Monoclonal antibody HB2-saporin conjugate

Drug Profile

Monoclonal antibody HB2-saporin conjugate

Alternative Names: Anti-CD7 monoclonal antibody HB2-saporin conjugate

Latest Information Update: 30 Apr 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Leukaemia

Most Recent Events

  • 06 May 1999 A preclinical study has been added to the pharmacodynamics section
  • 14 Sep 1998 Profile reviewed
  • 26 Aug 1996 Preclinical development for Leukaemia in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top